Japan to Approve Novo Nordisk's Wegovy and Taisho Pharmaceutical's Alli, Expanding Obesity Treatment Options

Kyodo News reported on February 8 that regarding the new injectable drug "Wegovy" for obesity patients applied by Japanese subsidiary of Danish pharmaceutical company Novo Nordisk, Japan's Ministry of Health, Labour and Welfare specialist panel has recently approved its production and sales, with formal approval expected soon; the Ministry also plans to approve Taisho Pharmaceutical’s oral medication "alli," which can be purchased at pharmacies. The report stated that after approximately 30 years, the options for obesity treatment drugs will increase.